Literature DB >> 10586117

FCgammaRII (CD32)-dependent induction of interferon-alpha by serum from patients with lupus erythematosus.

F Batteux1, P Palmer, M Daëron, B Weill, P Lebon.   

Abstract

Interferon-alpha (IFN-alpha) is detected in the serum of 70-80% of patients with systemic lupus erythematosus (SLE). Furthermore, soluble factors in SLE serum can induce peripheral blood mononuclear cells (PBMC) to produce IFN-alpha. The purpose of this work was to investigate the mechanism of this IFN-alpha induction. In eleven of fifteen SLE serum samples, an IFN-alpha inducing activity was detected, whereas serum from healthy controls, patients with other autoimmune disease and patients with viral infections were ineffective under the same conditions. After gel filtration of the serum, the inducing activity was found in the same fraction as IgG. The IFN-alpha inducing activity was inhibited by native monoclonal antibodies to the receptors for the Fc portion of IgG: FcgammaRIIA/C and FcgammaRIIB subclasses (CD32) and by their F(ab)'2 fragments. Purified Fc fragments of human IgG were also effective in abolishing the IFN-alpha-inducing activity. Since no anti-CD32 autoantibodies were found in SLE serum, this IFN-alpha-inducing activity may be due to immune complex antibodies. Such results may allow better understand the origin of endogenous IFN-alpha, which has a deleterious effect on the course of this autoimmune disease. The inhibition of this function by the CD32 antibody could lead to new therapeutic approach in SLE.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10586117

Source DB:  PubMed          Journal:  Eur Cytokine Netw        ISSN: 1148-5493            Impact factor:   2.737


  15 in total

1.  Immune complexes from SLE sera induce IL10 production from normal peripheral blood mononuclear cells by an FcgammaRII dependent mechanism: implications for a possible vicious cycle maintaining B cell hyperactivity in SLE.

Authors:  J Rönnelid; A Tejde; L Mathsson; K Nilsson-Ekdahl; B Nilsson
Journal:  Ann Rheum Dis       Date:  2003-01       Impact factor: 19.103

Review 2.  TLR7 and TLR9 in SLE: when sensing self goes wrong.

Authors:  T Celhar; R Magalhães; A-M Fairhurst
Journal:  Immunol Res       Date:  2012-09       Impact factor: 2.829

Review 3.  New insights into the immunopathogenesis of systemic lupus erythematosus.

Authors:  George C Tsokos; Mindy S Lo; Patricia Costa Reis; Kathleen E Sullivan
Journal:  Nat Rev Rheumatol       Date:  2016-11-22       Impact factor: 20.543

4.  Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9.

Authors:  Terry K Means; Eicke Latz; Fumitaka Hayashi; Mandakolathur R Murali; Douglas T Golenbock; Andrew D Luster
Journal:  J Clin Invest       Date:  2005-02       Impact factor: 14.808

Review 5.  Emerging therapies for systemic lupus erythematosus--focus on targeting interferon-alpha.

Authors:  Eben I Lichtman; Simon M Helfgott; Martin A Kriegel
Journal:  Clin Immunol       Date:  2012-04-06       Impact factor: 3.969

Review 6.  Interferon alpha in systemic lupus erythematosus.

Authors:  Timothy B Niewold; Daniel N Clark; Rafah Salloum; Brian D Poole
Journal:  J Biomed Biotechnol       Date:  2010-06-29

7.  IFNalpha kinoid vaccine-induced neutralizing antibodies prevent clinical manifestations in a lupus flare murine model.

Authors:  Daniel Zagury; Hélène Le Buanec; Alexis Mathian; Patrick Larcier; Roger Burnett; Zahir Amoura; Dominique Emilie; Gabriel Peltre; Armand Bensussan; Bernard Bizzini; Robert C Gallo; Sophie Koutouzov
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-11       Impact factor: 11.205

8.  Effects of IRF5 lupus risk haplotype on pathways predicted to influence B cell functions.

Authors:  Joel M Guthridge; Daniel N Clark; Amanda Templeton; Nicolas Dominguez; Rufei Lu; Gabriel S Vidal; Jennifer A Kelly; Kenneth M Kauffman; John B Harley; Patrick M Gaffney; Judith A James; Brian D Poole
Journal:  J Biomed Biotechnol       Date:  2012-02-22

Review 9.  A pivotal role for the natural interferon alpha-producing cells (plasmacytoid dendritic cells) in the pathogenesis of lupus.

Authors:  L Rönnblom; G V Alm
Journal:  J Exp Med       Date:  2001-12-17       Impact factor: 14.307

10.  TLR7-dependent and FcgammaR-independent production of type I interferon in experimental mouse lupus.

Authors:  Pui Y Lee; Yutaro Kumagai; Yi Li; Osamu Takeuchi; Hideo Yoshida; Jason Weinstein; Erinn S Kellner; Dina Nacionales; Tolga Barker; Kindra Kelly-Scumpia; Nico van Rooijen; Himanshu Kumar; Taro Kawai; Minoru Satoh; Shizuo Akira; Westley H Reeves
Journal:  J Exp Med       Date:  2008-12-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.